Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DNTH Dianthus Therapeutics	$20.59 -0.4%	$19.06	$13.36 ▼ $32.27	$662.17M	1.43	352,897 shs	370,878 shs
NAMS NewAmsterdam Pharma	$21.28 -2.4%	$20.18	$14.06 ▼ $27.29	$2.39B	-0.02	776,378 shs	537,520 shs
OGN Organon & Co.	$9.76 +0.6%	$9.78	$8.01 ▼ $23.10	$2.53B	0.6	3.43 million shs	3.69 million shs
RXRX Recursion Pharmaceuticals	$5.68 -4.5%	$5.28	$3.79 ▼ $12.36	$2.31B	0.93	31.26 million shs	17.93 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DNTH Dianthus Therapeutics	-0.39%	-4.23%	+12.02%	-5.12%	-30.86%
NAMS NewAmsterdam Pharma	-2.43%	-9.83%	+12.24%	+6.24%	+24.30%
OGN Organon & Co.	+0.67%	-4.08%	-3.94%	+1.67%	-55.33%
RXRX Recursion Pharmaceuticals	-4.54%	-12.48%	+9.02%	-0.35%	-30.73%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DNTH Dianthus Therapeutics	1.2535 of 5 stars	3.5	2.0	0.0	0.0	0.0	0.8	0.0
NAMS NewAmsterdam Pharma	3.3277 of 5 stars	4.4	1.0	0.0	0.0	2.1	5.0	0.0
OGN Organon & Co.	4.8725 of 5 stars	3.3	4.0	1.7	3.7	2.7	3.3	2.5
RXRX Recursion Pharmaceuticals	1.5288 of 5 stars	2.2	2.0	0.0	0.0	3.3	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DNTH Dianthus Therapeutics	3.00	Buy	$53.00	157.41% Upside
NAMS NewAmsterdam Pharma	2.89	Moderate Buy	$41.30	94.08% Upside
OGN Organon & Co.	2.50	Moderate Buy	$18.00	84.43% Upside
RXRX Recursion Pharmaceuticals	2.33	Hold	$7.00	23.24% Upside

Current Analyst Ratings Breakdown

Latest DNTH, OGN, NAMS, and RXRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/17/2025	NAMS NewAmsterdam Pharma	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$27.00
7/8/2025	RXRX Recursion Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
7/3/2025	RXRX Recursion Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$5.00
7/2/2025	DNTH Dianthus Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
6/17/2025	NAMS NewAmsterdam Pharma	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$42.00
6/16/2025	RXRX Recursion Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$8.00 ➝ $5.00
6/12/2025	NAMS NewAmsterdam Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00
6/10/2025	NAMS NewAmsterdam Pharma	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$44.00
6/4/2025	NAMS NewAmsterdam Pharma	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$42.00
5/22/2025	OGN Organon & Co.	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/15/2025	OGN Organon & Co.	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$24.00 ➝ $18.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DNTH Dianthus Therapeutics	$6.24M	106.12	N/A	N/A	$11.91 per share	1.73
NAMS NewAmsterdam Pharma	$45.56M	52.44	N/A	N/A	$8.20 per share	2.60
OGN Organon & Co.	$6.40B	0.40	$4.93 per share	1.98	$1.83 per share	5.33
RXRX Recursion Pharmaceuticals	$58.84M	39.24	N/A	N/A	$2.61 per share	2.18

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DNTH Dianthus Therapeutics	-$84.97M	-$2.88	N/A	N/A	N/A	-1,544.23%	-29.26%	-27.87%	8/6/2025 (Estimated)
NAMS NewAmsterdam Pharma	-$241.60M	-$1.88	N/A	N/A	N/A	-397.45%	-37.34%	-33.45%	8/6/2025 (Estimated)
OGN Organon & Co.	$864M	$2.88	3.39	2.61	1.01	11.92%	227.43%	7.34%	8/5/2025 (Estimated)
RXRX Recursion Pharmaceuticals	-$463.66M	-$1.77	N/A	N/A	N/A	-961.32%	-74.70%	-54.02%	8/5/2025 (Estimated)

Latest DNTH, OGN, NAMS, and RXRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	DNTH Dianthus Therapeutics	-$0.86	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	NAMS NewAmsterdam Pharma	-$0.52	N/A	N/A	N/A	$1.44 million	N/A
8/5/2025	Q2 2025	OGN Organon & Co.	$0.93	N/A	N/A	N/A	$1.55 billion	N/A
8/5/2025	Q2 2025	RXRX Recursion Pharmaceuticals	-$0.34	N/A	N/A	N/A	$15.38 million	N/A
5/12/2025	Q1 2025	DNTH Dianthus Therapeutics	-$0.86	-$0.82	+$0.04	-$0.82	$0.81 million	$1.16 million
5/8/2025	Q1 2025	NAMS NewAmsterdam Pharma	-$0.45	-$0.49	-$0.04	-$0.34	$1.46 million	$2.98 million
5/5/2025	Q1 2025	RXRX Recursion Pharmaceuticals	-$0.44	-$0.50	-$0.06	-$0.50	$18.12 million	$14.75 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DNTH Dianthus Therapeutics	N/A	N/A	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	N/A	N/A	N/A	N/A	N/A
OGN Organon & Co.	$0.08	0.82%	N/A	2.78%	N/A
RXRX Recursion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest DNTH, OGN, NAMS, and RXRX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/2/2025	OGN Organon & Co.	quarterly	$0.02	0.8%	5/12/2025	5/12/2025	6/12/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DNTH Dianthus Therapeutics	N/A	15.98	15.99
NAMS NewAmsterdam Pharma	N/A	19.98	19.98
OGN Organon & Co.	16.49	1.67	1.15
RXRX Recursion Pharmaceuticals	0.02	4.11	4.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DNTH Dianthus Therapeutics	47.53%
NAMS NewAmsterdam Pharma	89.89%
OGN Organon & Co.	77.43%
RXRX Recursion Pharmaceuticals	89.06%

Insider Ownership

Company	Insider Ownership
DNTH Dianthus Therapeutics	8.15%
NAMS NewAmsterdam Pharma	20.84%
OGN Organon & Co.	1.96%
RXRX Recursion Pharmaceuticals	8.43%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DNTH Dianthus Therapeutics	80	32.16 million	29.54 million	Optionable
NAMS NewAmsterdam Pharma	4	112.27 million	88.87 million	Optionable
OGN Organon & Co.	4,000	259.96 million	254.86 million	Not Optionable
RXRX Recursion Pharmaceuticals	400	406.49 million	372.23 million	Optionable

DNTH, OGN, NAMS, and RXRX Headlines

Recent News About These Companies

Recursion Pharmaceuticals (RXRX) Price Surges 9% Over Past Month

August 2 at 6:17 PM | finance.yahoo.com

Recursion Pharmaceuticals (RXRX) Expected to Announce Quarterly Earnings on Tuesday

August 1 at 4:55 PM | marketbeat.com

Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to Note

July 30 at 6:45 PM | zacks.com

Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today

July 29, 2025 | zacks.com

Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th

July 29, 2025 | globenewswire.com

Why Recursion Pharmaceuticals Stock Got Mashed on Monday

July 28, 2025 | fool.com

Tempus AI (TEM) vs. Recursion (RXRX): Which AI Biotech Stock Is Better?

July 28, 2025 | 247wallst.com

62,691 Shares in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Purchased by Cerity Partners LLC

July 28, 2025 | marketbeat.com

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Purchased by ARK Investment Management LLC

July 27, 2025 | marketbeat.com

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Sold by Nikko Asset Management Americas Inc.

July 27, 2025 | marketbeat.com

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Sold by Baillie Gifford & Co.

July 27, 2025 | marketbeat.com

The Median Retirement Savings for American Households Is $87,000. Here Are 3 Incredible Stocks to Buy Now and Hold for Decades.

July 26, 2025 | fool.com

How Palantir, Tempus, Nvidia-Backed Recursion Are Disrupting Big Pharma

July 25, 2025 | benzinga.com

RXRX vs. RLAY: Which Precision Biotech Stock is a Better Bet Now?

July 25, 2025 | zacks.com

Recursion Pharmaceuticals (RXRX) Stock Drops Despite Market Gains: Important Facts to Note

July 23, 2025 | zacks.com

Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses?

July 23, 2025 | zacks.com

Recursion Pharmaceuticals (RXRX) Jumps 9.6% Ahead of Q2 Earnings

July 22, 2025 | insidermonkey.com

Pier 88 Investment Partners LLC Sells 66,940 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

July 22, 2025 | marketbeat.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Up - Time to Buy?

July 21, 2025 | marketbeat.com

Recursion Pharmaceuticals (RXRX) Soars 5.8%: Is Further Upside Left in the Stock?

July 21, 2025 | zacks.com

Recursion Pharmaceuticals Acquires Full Rights to REV102, Potential Oral Therapy for Rare Bone Disorder Hypophosphatasia

July 21, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNTH, OGN, NAMS, and RXRX Company Descriptions

Dianthus Therapeutics NASDAQ:DNTH

$20.59 -0.08 (-0.39%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$21.00 +0.41 (+1.99%)

As of 08/1/2025 04:18 PM Eastern

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

NewAmsterdam Pharma NASDAQ:NAMS

$21.28 -0.53 (-2.43%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$21.28 0.00 (0.00%)

As of 08/1/2025 06:13 PM Eastern

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Organon & Co. NYSE:OGN

$9.76 +0.06 (+0.62%)

Closing price 08/1/2025 03:59 PM Eastern

Extended Trading

$9.64 -0.12 (-1.18%)

As of 08/1/2025 06:32 PM Eastern

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Recursion Pharmaceuticals NASDAQ:RXRX

$5.68 -0.27 (-4.54%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$5.62 -0.06 (-1.06%)

As of 08/1/2025 08:00 PM Eastern

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time